Introduction: What they say:
A study from the Stem Cell Transplantation Program, Division of Pediatric Hematology/Oncology, Boston Children’s Hospital and Dana-Farber Cancer Institute, Boston, Massachusetts, USA shows that “The Lin28/let-7 axis regulates glucose metabolism.” This study was published, in the 30 September 2011 issue of the Journal “Cell” [One of the best journals in Biological Sciences, with an I.F of 28.71], by Prof George Q, the present Dean of the Harvard Medical School, Zhu H, and others.
What we say:
On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that: Ramipril-based therapy for DM: Ramipril (trade names: Altace, Prilace Novapril, Ramitens, Ampril, Corpril, Piramil, Prilinda and others),), a drug used in the treatment of hypertension and cardiac dysfunction, increases the expression of IGF1R, INSR, and IRS2, and promotes an insulin-sensitized state, via up-regulation of its target gene Lin28
From the significance of the study to Public health relevance:
Given that: (1) more than 387 million people worldwide are affected by Diabetes mellitus (DM); (2) Diabetes is going to be one of the top 10 causes of death by 2030; (3) the life-long painful injection/drug treatment is required to treat DM; (3) the global economic cost spent for diabetes treatment in 2014 was little more than 600 billion US dollars, there is an urgent need to find: (i) a way to induce regeneration of adult ß-cells and cardiomyocytes that were lost in DM (Diabetes Mellitus) and MI (Myocardial infarction), respectively; (ii) a cheaper alternative to the existing expensive weight-loss drugs; (iii) a side-effect-free natural product-based drug; and (iv) a way to cure, not just treat, diabetes.
What is known?
Prof. George Q and his research team members had shown earlier that loss of Lin28 in muscles promotes insulin resistance and glucose intolerance.
Research findings to Therapeutic opportunity:
Ramipril, by increasing the expression of its target gene, it may increase the expression of Lin-28. Thereby, it may (1) increase the expression of IGF1R, INSR, and IRS2; (2) enhance tissue repair; (3) promote regeneration of pancreatic β-cells; (3) augment regenerative capacity; (4) promote insulin sensitivity; and (5) protect against DM and dilated cardiomyopathy (DCM) (Fig.1). Thus, pharmacological formulations encompassing “Ramipril or Ramiprilat or its analogs, either alone or in combination with other drugs,” may be used to treat DM and DCM (Fig.2).
Given the mechanistic basis of how Ramipril may aid in bringing down glucose levels and increasing insulin sensitivity, medical practitioners and diabetologists may consider treating diabetic/hypertensive/cardiac patients with Ramipril or its metabolite Ramiprilat.
Details of the research findings:
Idea Proposed/Formulated (with experimental evidence) by:
Dr L Boominathan Ph.D.
Amount: $ 500#
Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/
Undisclosed mechanistic information: How does Ramipril promote insulin-sensitized state?
# Research cooperation
Citation: Boominathan L, Molecular therapy for Diabetes Mellitus: Ramipril (trade names: Altace, Prilace Novapril, Ramitens, Ampril, Corpril, Piramil, Prilinda and others),), a drug used in the treatment of hypertension and cardiac dysfunction, increases the expression of IGF1R, INSR, and IRS2, and promotes an insulin-sensitized state, via up-regulation of its target gene Lin28, 28/December/2018, 10.12 pm, Genome-2-BioMedicine Discovery center (GBMD), http://genomediscovery.org
Courtesy: When you cite drop us a line at firstname.lastname@example.org